Cross-Sector entity
Firdapse is most often covered alongside Agamree, which appears in 2 of these 2 stories. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Firdapse is most often covered alongside Agamree, which appears in 2 of these 2 stories. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. Firdapse appears in 2 tracked Cross-Sector stories from February 24, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Firdapse. Shared-story counts are live from our verified record — not editorial picks.
Catalyst Pharmaceuticals (CPRX) and Root (ROOT) are scheduled to release their quarterly financial results this Wednesday, February 25. For Catalyst, the report will be a critical barometer for the commercial uptake of its newly launched DMD treatment, Agamree, and the continued stability of its flagship LEMS therapy, Firdapse.
Root and Catalyst Pharmaceuticals are scheduled to release their quarterly financial results this Wednesday, providing critical data points for the insurtech and orphan drug sectors. Investors are looking for Root's progress toward profitability and Catalyst's continued dominance in the LEMS market.
Source: tickerreport.com · dailypolitical.com
